靶向药物索拉非尼联合立体定向放射治疗肝癌肺转移的临床疗效及安全性研究  

Clinical efficacy and safety of targeted drug sorafenib combined with stereotactic radiotherapy in treating lung metastasis of hepatocellular carcinoma

作　　者：朱中山[1] 严文辉[1] 李小兵[1] 江承川 李湘军 彭新茂[1] 曾春亚 杨洲[1] Zhu Zhongshan;Yan Wenhui;Li Xiaobing;Jiang Chengchuan;Li Xiangjun;Peng Xinmao;Zeng Chunya;Yang Zhou(Oncology Department,The Second People’s Hospital of Hunan Province,Changsha 410007,China)

机构地区：[1]湖南省第二人民医院肿瘤科,长沙410007

出　　处：《广西医科大学学报》2020年第6期1144-1148,共5页Journal of Guangxi Medical University

基　　金：湖南省卫生厅科研基金资助项目(No.B2013-087)。

摘　　要：目的:探讨靶向药物索拉非尼联合立体定向放射治疗肝癌肺转移的临床疗效及安全性。方法:选取2013年1月至2015年1月于湖南省第二人民医院肿瘤科就诊的肝癌肺转移患者84例为研究对象,按随机数字表法分为索拉非尼治疗组(n=28),放射治疗组(n=28)与联合治疗组(n=28),索拉非尼治疗组给予靶向药物索拉非尼治疗,放射治疗组给予立体定向放射治疗,联合治疗组给予靶向药物索拉非尼联合立体定向放射治疗,对比3组患者的临床疗效、不良反应的发生情况、生存率及中位生存期,同时,通过比较治疗前与治疗后3组患者的NK细胞和白细胞介素-2(IL-2)含量来评估患者免疫力改善情况。结果:联合治疗组患者的治疗总有效率和1年、2年生存率均显著高于索拉非尼治疗组和放射治疗组,中位生存期显著长于索拉非尼治疗组和放射治疗组(P<0.05)。联合治疗组不良反应发生率为35.71%(10/28),索拉非尼治疗组为28.57%(8/28),放射治疗组为32.14%(9/28),3组患者的不良反应发生率比较,无明显差异(χ2=0.325,P=0.706)。3组患者治疗后的NK细胞和IL-2含量均显著高于治疗前,且在治疗2个月后,联合治疗组NK细胞和IL-2含量显著高于索拉非尼治疗组和放射治疗组(P<0.05)。结论:靶向药物索拉非尼联合立体定向放射治疗肝癌肺转移的临床疗效好,能够有效延长患者的生存期,且不增加不良反应,值得临床推广。Objective:To investigate the clinical efficacy and safety of targeted drug sorafenib in combination with stereotactic radiotherapy in treating lung metastasis of hepatocellular carcinoma(HCC).Methods:Eightyfour patients with lung metastasis of HCC treated in ourhospital from Jan.2013 to Jan.2015 were selected and randomly divided into sorafenib treatment group(n=28),radiotherapy group(n=28),and combined treatment group(n=28)by random table method.Sorafenib treatment group was treated with targeted drug sorafenib,radiotherapy group was given stereotactic radiotherapy,and the combined treatment group was treated with sorafenib in combination with stereotactic radiotherapy.The clinical efficacy,adverse reactions,survival rate,and median survival time of the three groups were compared.At the same time,the improvement of immunity was evaluated by comparing the contents of NK cells and interleukin-2(IL-2)among the three groups before and after treatment.Results:The total effective rate and 1-year and 2-year survival rate of patients in combinedtreatment group were significantly higher than those in sorafenib group and radiotherapy group,and the median survival time in combination group was significantly longer than that in sorafenib group and radiotherapy group(P<0.05).The incidence of adverse reactionsin the combined treatment group was 35.71%(10/28),in the sorafenib groupwas28.57%(8/28),and in the radiotherapy groupwas 32.14%(9/28).There was no significant difference in the incidence of adverse reactions among the three groups(χ2=0.325,P=0.706).The contents of NK cells and IL-2 among the three groups were significantly higher after treatment than those before treatment,and the contents of NK cells and IL-2 in the combined treatment group were significantly higher than those in the sorafenib group and radiotherapy group after 2 months of treatment(P<0.05).Conclusion:The clinical effect of targeted drug sorafenib in combination with stereotactic radiotherapy for lung metastasis of HCCtreatment is positive,which can ef

关 键 词：肝癌肺转移 靶向药物 索拉非尼 立体定向放疗 

分 类 号：R735.7[医药卫生—肿瘤]